Between 2010 and 2013, a total of 19 patients were enrolled. The majority of histology was squamous cell carcinoma (10/19). One patient had gross residual disease following surgical resection. With follow-up up to 44 months (median 15, range 1-44 months), 9 patients developed another recurrence or progression of HN cancer, including the patient who had gross residual disease after attempted surgery. In 5 of these 9 cases, the failure was locoregional and in 2 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. Median overall survival is 15 months and disease free survival is 12 months. The 6, 12 and 18 month OS was 77%, 71% and 45%. The 6, 12 and 18 month LRFS was 69%, 62% and 52%. The 6, 12 and 18 month DFS was 61%, 48% and 40%. Two patients developed Grade 3 toxicity; all other complications were Grade 1-2 with no Grade 4 or 5 complications. The exposure rate with Cs-131 was found to be acceptable.
Compared to prior literature, our study shows that use of concurrent Cs-131 brachytherapy achieves excellent rates of local control and survival. In addition, the implant related exposure to staff was minimal, and there was no grade 4 or 5 toxicity despite re-irradiation in most patients.
i bet you he is shorting isoray
IsoRay up premarket on brain cancer results
Nano cap IsoRay (NYSEMKT:ISR) jumps 35% premarket on robust volume in response to its press release on the performance of its Cesium-131 in 27 patients with advanced brain cancers who had received as many as four prior therapies that failed.In a study conducted by researchers at Barrow Neurological Institute in Phoenix, AZ patients received an intensive dose of Cesium-131-based radiation in tandem with surgical removal of malignant growths. 26 of the 27 patients (96%) had not experienced a recurrence of the treated cancer with the treated bed during the follow-up period, although the length of the follow-up period is not disclosed. Also, the absence of recurrent cancer in the treated bed may be due to the completeness of the surgery instead of the Cesium-131.
but the difference is that they did not have a monopoly on PAL-103, I-125 like Isoray has with cesium-131
IsoRay Inc. (NYSE MKT:ISR), announced the striking results of a study of brain cancer patients treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer therapy. The findings of the study, conducted by researchers at Barrow Neurological Institute, were presented at the November 2014 annual meeting of the Society for Neuro-Oncology in Miami, Florida. On last trading day IsoRay, Inc. (NYSEMKT:ISR) moved up 13.58% to close at $1.84. Its volatility for the week is 8.08% while volatility for the month is 6.76%. ISR’s sales growth for past 5 years was -4.90% and its EPS growth for past 5 years was 9.90%. IsoRay, Inc. (NYSEMKT:ISR) monthly performance is 13.58%.
Brain Cancer results were already released and presented to The Society Fir Neuro-Ocology In Miami Florida last month. Lung Study was also presented so expect those results in PR by xmas.
sleekmoneyDOTcom / short-interest-in-isoray-declines-by-9-1-isr/ 78905 /
Sentiment: Strong Buy
Total Shares Short 2,756,466
redjournalDOTorg/ article/ S0360-3016(14)02233-0/ fulltext
My friend on facebook who is a senior analyst at Global Investment Performance Standards at CFA Institute says isoray could be in that quiet period now with a potential suitor